Research Article


Open Access
DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF
View ORCID ProfileNuria Gutierrez-Prat, View ORCID ProfileHedwig L Zuberer, View ORCID ProfileLuca Mangano, View ORCID ProfileZahra Karimaddini, View ORCID ProfileLuise Wolf, View ORCID ProfileStefka Tyanova, View ORCID ProfileLisa C Wellinger, View ORCID ProfileDaniel Marbach, Vera Griesser, View ORCID ProfilePiergiorgio Pettazzoni, James R Bischoff, View ORCID ProfileDaniel Rohle, View ORCID ProfileChiara Palladino, View ORCID ProfileIgor Vivanco
Nuria Gutierrez-Prat
1Roche Pharma Research and Early Development, Oncology Discovery, Roche Innovation Center Basel, Basel, Switzerland
Hedwig L Zuberer
1Roche Pharma Research and Early Development, Oncology Discovery, Roche Innovation Center Basel, Basel, Switzerland
Luca Mangano
1Roche Pharma Research and Early Development, Oncology Discovery, Roche Innovation Center Basel, Basel, Switzerland
Zahra Karimaddini
2Roche Pharma Research and Early Development, Informatics, Roche Innovation Center Basel, Basel, Switzerland
Luise Wolf
2Roche Pharma Research and Early Development, Informatics, Roche Innovation Center Basel, Basel, Switzerland
Stefka Tyanova
2Roche Pharma Research and Early Development, Informatics, Roche Innovation Center Basel, Basel, Switzerland
Lisa C Wellinger
4Ridgeline Discovery Basel, Basel, Switzerland
Daniel Marbach
3Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland
Vera Griesser
3Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland
Piergiorgio Pettazzoni
1Roche Pharma Research and Early Development, Oncology Discovery, Roche Innovation Center Basel, Basel, Switzerland
James R Bischoff
1Roche Pharma Research and Early Development, Oncology Discovery, Roche Innovation Center Basel, Basel, Switzerland
Daniel Rohle
4Ridgeline Discovery Basel, Basel, Switzerland
Chiara Palladino
1Roche Pharma Research and Early Development, Oncology Discovery, Roche Innovation Center Basel, Basel, Switzerland
Igor Vivanco
5Institute of Pharmaceutical Science, King’s College London, London, UK
Published 17 May 2022. DOI: 10.26508/lsa.202101235

Statistics from Altmetric.com
Article usage
DUSP4 restricts MAPK overdose in melanoma
Nuria Gutierrez-Prat, Hedwig L Zuberer, Luca Mangano, Zahra Karimaddini, Luise Wolf, Stefka Tyanova, Lisa C Wellinger, Daniel Marbach, Vera Griesser, Piergiorgio Pettazzoni, James R Bischoff, Daniel Rohle, Chiara Palladino, Igor Vivanco
Life Science Alliance May 2022, 5 (9) e202101235; DOI: 10.26508/lsa.202101235
DUSP4 restricts MAPK overdose in melanoma
Nuria Gutierrez-Prat, Hedwig L Zuberer, Luca Mangano, Zahra Karimaddini, Luise Wolf, Stefka Tyanova, Lisa C Wellinger, Daniel Marbach, Vera Griesser, Piergiorgio Pettazzoni, James R Bischoff, Daniel Rohle, Chiara Palladino, Igor Vivanco
Life Science Alliance May 2022, 5 (9) e202101235; DOI: 10.26508/lsa.202101235
In this Issue
Volume 5, No. 9
September 2022
Advertisement
Jump to section
Subjects
Related Articles
- No related articles found.
Cited By...
- No citing articles found.